IE 11 is a very old Browser and it`s not supported on this site

Consolidated statement of comprehensive income for the year ended December 31

in CHF 1 000

Notes

2023

2022

Operating income

Interest income

35

4

Foreign exchange gains

490

1 253

Other income

5

4

530

1 261

Operating expenses

Losses from securities

4

(166 613)

(314 265)

Finance expenses

(5 802)

(1 726)

Administrative expenses

8

(30 083)

(38 747)

Other expenses

9

(4 560)

(4 274)

(207 058)

(359 012)

Profit/(loss) before tax

12

(206 528)

(357 751)

Income taxes

10

(79)

(61)

Profit/(loss) for the period

(206 607)

(357 812)

Total comprehensive profit/(loss) for the period

(206 607)

(357 812)

Earnings per share in CHF

11

(3.77)

(6.50)

Diluted earnings per share in CHF

11

(3.77)

(6.50)

The notes are an integral part of the consolidated financial statements.

BB Biotech AG uses cookies to improve website usability and ensure the best possible user experience. Use of cookies & disclaimer